Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.61 |
| ▸ | CES2 | O00748 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 10/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CHRND | Q07001 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628387 | 1.00 | PTPN1 (0.61) | PTPN1CES2CES1GSK3BKMT2A | |
| SCHEMBL1701124 | 0.84 | PTPN1 (0.57) | PTPN1GSK3B | |
| SCHEMBL31149832 | 0.84 | PTPN1 (0.57) | PTPN1CES2CES1GSK3BNPC1 | |
| SCHEMBL29471126 | 0.84 | PTPN1 (0.57) | PTPN1GSK3B | |
| SCHEMBL2953875 | 0.84 | PTPN1 (0.57) | PTPN1CES2CES1GSK3B | |
| SCHEMBL3162903 | 0.84 | PTPN1 (0.57) | PTPN1CES2CES1GSK3BNPC1 | |
| SCHEMBL311275 | 0.82 | GSK3B (0.60) | PTPN1GSK3BNPC1RAB9A | |
| SCHEMBL3973133 | 0.82 | GSK3B (0.55) | PTPN1GSK3B | |
| SCHEMBL29977610 | 0.82 | GSK3B (0.55) | PTPN1GSK3BKMT2A | |
| SCHEMBL29499477 | 0.82 | GSK3B (0.55) | PTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773196-B | Purification method of high-carbon methacrylate | 辽宁华星日化产业技术研究院有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-114773196-A | Method for purifying methacrylic acid high-carbon ester | 辽宁华星日化产业技术研究院有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250223307-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4582420-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Global Health Drug Discovery Institute (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-12258323-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-3997096-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024104304-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京华益健康药物研究中心 | 2024-05-23 | — | — | WO | disclosed |
| CN-111212647-B | Dihydro oxadiazinones | 拜耳股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117820192-A | Gamma-lactam ring compound and preparation method and application thereof | 重庆理工大学 | 2024-04-05 | — | — | CN | disclosed |
| EP-1020426-A1 | AMINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0411252-B1 | Process for the preparation of fluorobenzoic acids | RIEDEL DE HAEN AG (DE) | 1993-11-03 | — | — | EP | disclosed |
| US-5093529-A | Process for the preparation of fluorinated benzoic acids | CASSELLA AKTIENGESELLSCHAFT (DE) | 1992-03-03 | — | — | US | disclosed |
| EP-0411252-A1 | Process for the preparation of fluorobenzoic acids | RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) | 1991-02-06 | — | — | EP | disclosed |
| EP-0342849-A2 | Intermediates for preparing 1,4-dihydro-4-oxo-quinoline-3-carboxylic acid esters | PFIZER INC. (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0016277-B1 | 2-CARBONYL-3-HYDROXY-ALKENONITRILES, THEIR USE AS ANTI-ARTHRITIC AGENTS AND PROCESSES FOR THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1981-12-02 | — | — | EP | disclosed |
| EP-0016277-A1 | 2-Carbonyl-3-hydroxy-alkenonitriles, their use as anti-arthritic agents and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-10-01 | — | — | EP | disclosed |
| WO-1980000964-A1 | ANTI-INFLAMMATORY AGENTS INCLUDING 2-CARBONYL-3-HYDROXY-2-ALKENONITRILES | AMERICAN CYANAMID CO (US) | 1980-05-15 | — | — | WO | disclosed |
| US-4173650-A | ANTIARTHRITIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258323-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | PTPN1 2650/4885CES2 4389/4885CES1 2438/4885 |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | PTPN1 2849/4885CES2 166/4885CES1 229/4885 |
| US-20250223307-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | MDM2, TP53, TP53BP1 | PTPN1 876/4885CES2 4826/4885CES1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.